Cette liste est basée sur les listes de surveillance des personnes sur Stock Events qui suivent NRBO. Il ne s'agit pas d'une recommandation d'investissement.
Sur la base de 1 notations au cours des 6 derniers mois. Il ne s'agit pas d'une recommandation d'investissement.
Acheter
100%
Détenir
0%
Vendre
0%
À propos de nous
Health Technology
Pharmaceuticals: Major
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.